Orexo AB
STO:ORX
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
828.1m SEK |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
923.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
582.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
253.4B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.8B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
152.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.7B USD |
Loading...
|
Market Distribution
| Min | -2 025 693.8% |
| 30th Percentile | -1.8% |
| Median | 6% |
| 70th Percentile | 12.5% |
| Max | 10 459.2% |
Other Profitability Ratios
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Orexo AB is -1 356.5%, which is below its 3-year median of -252.5%.
Over the last 3 years, Orexo AB’s Operating Margin has decreased from -30.6% to -1 356.5%. During this period, it reached a low of -1 356.5% on Jan 1, 2026 and a high of -8.5% on Sep 30, 2024.
